Thank you for giving this guide a go. The idea behind this is to make things easier for you when you lead the journal club.

Journal clubs are often difficult to conduct and far removed from clinical life. Even if the leaders do prepare well, those turning up may be more in need of lunch, coffee or a social time than practical academic stimulation and the implicit pressure to read a difficult paper.

This suggested design is an attempt to allow for those needs, whilst getting the very best out of the session.

This journal club design should really help those attending see that this research may have some clinical value.

What you will need to do is:

☑ Have a good read of this
☑ Then read the review to which this is attached.
☑ Distribute the review to those attending well before the club
☑ Make more copies for those turning up on spec
☑ Do not really expect many to have read the review

Background explanation

Thank you for giving this guide a go. The idea behind this is to make things easier for you when you lead the journal club.

Journal clubs are often difficult to conduct and far removed from clinical life. Even if the leaders do prepare well, those turning up may be more in need of lunch, coffee or a social time than practical academic stimulation and the implicit pressure to read a difficult paper.

This suggested design is an attempt to allow for those needs, whilst getting the very best out of the session.

This journal club design should really help those attending see that this research may have some clinical value.

What you will need to do is:

☑ Have a good read of this
☑ Then read the review to which this is attached.
☑ Distribute the review to those attending well before the club
☑ Make more copies for those turning up on spec
☑ Do not really expect many to have read the review

The three parts

Part 1. Set the clinical scene (5 mins)

Be clear, but really make the participants feel the pressure of the situation...just like you would in clinical life

Part 2. Critical appraisal of the review (20 mins)

Get participants to list what is needed from the review before John arrives, get them to talk, split into groups—with a feeling of urgency.

Part 3. Use of evidence in clinical life (20 mins)

Having distilled the evidence use role play to see how the participants would use what they have learned in everyday life.
Part 1.1 Setting the scene – John

Introduce participants in the journal club to their scenario

John is 30 years old. He has had schizophrenia for 10 years and been treated with various anti-psychotic medications. He began to develop disfiguring tardive dyskinesia quite swiftly after being changed to the newer generation drugs. His psychotic symptoms are reasonably well controlled. He is articulate and intelligent and handsome. He is greatly disfigured by the tardive dyskinesia that shows no sign of easing off over time. He has done his homework and knows there are a variety of other drugs that can be used for this condition. He does not want to change anti-psychotic treatment or modify the current dose he is on. He is coming to see you this afternoon to discuss options.

Questions for participants:
Q 1. What do you think John may ask?
A 1. [Suggestion]: “Any fantastic new treatments for tardive dyskinesia?”
Q 2. “Any fantastic old treatments for tardive dyskinesia?”
A 2. List the suggestions from participants as these are what John will come back to in the role play
Q 3. “I have heard some places that Vitamin E could be of use, what do you think?”
A 3. Again, list answers.

Part 1.2 Setting the scene – the Journal club

Complicate the scenario by adding the need to attend this journal club

Knowing you are due to see John in less than an hour you are nevertheless compelled to attend journal club.

You have not had time to read the paper and need some lunch.

By a stroke of luck the paper for discussion focuses on the value of Vitamin E for tardive dyskinesia.

Questions for participants:
Q 1. If you had not had this paper fall into your lap where might you have gone for reliable information?
A 1. There are now lots of answers to this - The Cochrane Library, Clinical Evidence, NICE Technology Appraisals.

Anything that has a reproducible method by which results are obtained.

List 1:

1. 
2. 
3. 
4. 
5.

List 2:

1. 
2. 
3. 
4. 
5.

Part 2.1 Critical appraisal of the review

For every review there are only three important questions to ask:

1. Are the results valid?
2. What are the results?
3. Are the results applicable to service user?

Suggestion: Ask participants what salient facts they want to know - especially considering their tight time-scale.

Remind them that John now arrives in about 20 mins.

You should be able to fit most of the suggestions supplied by participants into the three categories of question outlined above.

Read 2.2 as this give more detail of the issues that will, in some shape or form, be supplied by the participants.

If they are not lively - give them a hand.

Do not panic. Bright journal club attendees will come up with all the answers - your job is to help focus their efforts and categorise their answers.

Do not be worried by silence.

Participants will think of most of the issues - you just need to catch them and write them on a board or flip chart.
Part 2.2 The three parts of appraising a review

1. Are the results valid?

There is no point looking at the result if they are clearly not valid.

a. Did the review address a clearly focused issue?

Did the review describe the population studied, intervention given, outcomes considered?

b. Did the authors select the right sort of studies for the review?

The right studies would address the review’s question, have an adequate study design

c. Do you think the important, relevant studies were included?

Look for which bibliographic databases were used, personal contact with experts, search for unpublished as well as published studies, search for non-English language studies

d. Did the review’s authors do enough to assess the quality of the included studies?

Did they use description of randomization, a rating scale?

2. What are the results?

a. Were the results similar from study to study?

Are the results of all included studies clearly displayed?

Are the results from different studies similar?

If not, are the reasons for variations between studies discussed?

b. What is the overall result of the review?

Is there a clinical bottom-line?

What is it?

What is the numerical result?

c. How precise are the results?

Is there a confidence interval?

3. Can I use the results to help John?

a. Can I apply the results to John?

Is John so different from those in the trial that the results don’t apply?

b. Should I apply the results to John?

How great would the benefit of therapy be for John?

Is the intervention consistent with John’s values and preferences?

Were all the clinically important outcomes considered?

Are the benefits worth the harms and costs?

Part 2.3 Doing the appraisal

Having managed the interactive session with the participants - acquiring the three questions that need to be addressed by those appraising a review and some idea of how to answer each of those questions - now divide the room into three.

Apportion one of the questions per group and ask each group to get a feel for the whole review (1 min) but to focus on answering their particular question for the rest of the participants (5 mins or so).

Encourage talking to each other.

Move round the room to help the groups if they seem to need it.

Have your copy of the review marked up with where they may look for answers - although in a good review it should be obvious.

Stop the flow after about 10 minutes and ask each group to report in turn.

Do Group 1 really think that the review uses valid methods? Why?

After the first group’s report you may want to ask everyone to vote whether to proceed or not. If they agree to proceed see if you can get Group 2 to give you the clinical bottom line.

We suggest that Graph 1.1 - ‗Tardive dyskinesia: 1. Not improved to a clinically important extent‘ is a good one to use to answer John’s question.

And from Group 3 get some feel of how applicable the findings are.

Well Doc, what’s the chances of vitamins reducing these movements?”
Part 2.4 A quick and dirty way to work out NNT

Comparison 1: VITAMIN E versus PLACEBO
Outcome: 1.1 Tardive dyskinesia: 1. Not improved to a clinically important extent

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Vitamin E</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Placebo</td>
<td>M-H, Fixed</td>
</tr>
<tr>
<td>Elkind 1968</td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>4.4%</td>
</tr>
<tr>
<td>Schmidt 1961</td>
<td>11</td>
<td>13</td>
<td>10</td>
<td>9.4%</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>16</td>
<td>15</td>
<td>15</td>
<td>13.8%</td>
</tr>
</tbody>
</table>

Heterogeneity: Chisq = 0.46, df = 1 (P = 0.50), P = 0%
Test for overall effect: Z = 0.31 (P = 0.37)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Vitamin E</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Placebo</td>
<td>M-H, Fixed</td>
</tr>
<tr>
<td>Adler 1993</td>
<td>15</td>
<td>17</td>
<td>11</td>
<td>12.0%</td>
</tr>
<tr>
<td>Lam 1994</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>0.3%</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>23</td>
<td>19</td>
<td>19</td>
<td>17.4%</td>
</tr>
</tbody>
</table>

Heterogeneity: Chisq = 0.06, df = 1 (P = 0.81), P = 0%
Test for overall effect: Z = 0.28 (P = 0.77)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Vitamin E</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Placebo</td>
<td>M-H, Fixed</td>
</tr>
<tr>
<td>Adler 1993</td>
<td>68</td>
<td>72</td>
<td>82</td>
<td>60.3%</td>
</tr>
<tr>
<td>Galajd 1995</td>
<td>11</td>
<td>11</td>
<td>9</td>
<td>0.3%</td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>84</td>
<td>94</td>
<td>94</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

Heterogeneity: Chisq = 0.12, df = 1 (P = 0.73), P = 0%
Test for overall effect: Z = 0.47 (P = 0.31)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Vitamin E</th>
<th>Placebo</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Events</td>
<td>Total</td>
<td>Placebo</td>
<td>M-H, Fixed</td>
</tr>
<tr>
<td></td>
<td>79</td>
<td>91</td>
<td>91</td>
<td>100.0%</td>
</tr>
</tbody>
</table>

Heterogeneity: Chisq = 0.97, df = 6 (P = 0.97), P = 0%
Test for overall effect: Z = 1.20 (P = 0.23)

Above graph shows, across any period of time 118 out of 127 people had no improvement on Vitamin E (93%), this was compared to 125 people out of 129 given placebo (97%). According to these results, the difference that seems attributable to the giving of Vitamin E is a matter of about 4% (97% minus 93% = 4%). Just round up or down to make it easy. Lets say, in this case, 5%. So 5% of people in these trials seem to get some sort of improvement from Vitamin E – or put another way, 1 in 20, or put another way NNT = 20.

Part 3. John arrives

This is the most important part of the journal club - the practical application of what knowledge you have gained.

This is one way of doing it. Set out two chairs in consultation style. Do not call for a volunteer- just nominate someone to be the clinician and you be John.

Make sure that the clinician feels they can have time to ask their [relieved for not being singled out] colleagues for help [remember- this has got to be a combination of practical and fun].

Back on page 2 there are suggestions for what John may ask- use them.

“Any fantastic new treatment for tardive dyskinesia?”
See if they can put across in a supportive way the best evidence as they understand it.

There is no perfect way to do this - but how do you (and probably not for the first time to John) break the news that this very long standing adverse effect is likely to be with him for a considerable period of time?

“I have heard some places that Vitamin E could be of use, what do you think?”
Again there is no right answer but think about how to put into words what the research outcome really means.

Perhaps - “the best evidence we have is from a Cochrane review, which suggests that for people not too dissimilar to you, taking Vitamin E has a slim chance of helping the tardive dyskinesia, but we are not sure. The data also do not rule out the possibility that it could even make things worse. It might be as good as about 1 in 10 people receiving some benefit, if given this treatment, or as bad as about 1 in 50 getting worse from it.”

As has been said- there is no right answer and all depends on personal style and situation. Your job is to encourage the best answer out of the clinician.

If it is going well there are other questions that you may ask- see side Box 1.

Limits of using this means of calculating NNT is that it does not take into account the baseline risk of the control group and does not give confidence intervals. As can be seen from the graph, it is also possible that Vitamin E has no effect whatsoever. The small diamond crosses the line of no effect and is compatible with a real (albeit small) effect of Vitamin E for the positive - but also for the negative.

In this case factoring in baseline risk of the control group does not make much of a difference, but considering the confidence intervals does highlight how this can be both beneficial (number needed to treat, to benefit NNTB) or harm (number needed to harm NNTH). Calculated number needed to treat 26, NNTB 11 to NNTH 52.

NNT = 26, CI (11 to 52)

http://www.nntonline.net/ebm/visualrx/examples/statins/
Vitamin E for neuroleptic-induced tardive dyskinesia
- HANDOUT FOR PARTICIPANTS

Produced by the Editorial base of the Cochrane Schizophrenia Group
http://szg.cochrane.org/en/index.html, email: jun.xia@nottingham.ac.uk

from

John will arrive soon

What do you think John may ask?

List:
1.
2.
3.
4.

What key points do you need to know to see if this review can help?*

1.
2.
3.
4.
5.

*John arrives in 30 mins

Special points of interest:
- The idea of this is to lead you from the clinical situation, through the research and back to the real-world clinical situation again
- You may or may not have read the paper - but even if you have not that does not mean that you cannot get something out of this
- Make sure you participate, and speak up - you will have to in the real clinic
- There is no perfect way of doing this - each person has an individual way of interacting and conveying information

If you had not had this paper fall into your lap where might you have gone for reliable information?
After discussion do you want to change the key points you need to know to see if this review can help?*

1.

2.

3.

*John arrives in 10 mins

Can you extract numbers that will be useful to you and John?
Clue: focus on what you think John may ask - main effects and adverse effects - graph number ‘1.1’ may be a good one to use

1. Can you put relative risk into words?

2. Can you see any improvements attributable to use of Vitamin E?

3. Can you work out the number needed to treat?

4. Can you put that into words?

John arrives
Is there a good use of words you would want to use?
Vitamin E for neuroleptic-induced tardive dyskinesia

- PARTICIPANTS’ CRIB SHEET

The three parts of appraising a review

1. Are the results valid?

   There is no point looking at the result if they are clearly not valid.

   a. Did the review address a clearly focused issue?

      Did the review describe the population studied, intervention given, outcomes considered?

   b. Did the authors select the right sort of studies for the review?

      The right studies would address the review’s question, have an adequate study design

   c. Do you think the important, relevant studies were included?

      Look for which bibliographic databases were used, personal contact with experts, search for unpublished as well as published studies, search for non-English language studies

   d. Did the review’s authors do enough to assess the quality of the included studies?

      Did they use description of randomization, a rating scale?

2. What are the results?

   a. Were the results similar from study to study?

      Are the results of all included studies clearly displayed?

   b. What is the overall result of the review?

      Is there a clinical bottom line?

      What is it?

      What is the numerical result?

   c. How precise are the results?

      Is there a confidence interval?

3. Can I use the results to help John?

   a. Can I apply the results to John?

      Is John so different from those in the trial that the results don’t apply?

   b. Should I apply the results to John?

      How great would the benefit of therapy be for John?

      Is the intervention consistent with John’s values and preferences?

      Were all the clinically important outcomes considered?

      Are the benefits worth the harms and costs?

A quick and dirty way to work out NNT (Graph 1.1)

Graph 1.1 shows that across any period of time 118 out of 127 people had no improvement on Vitamin E (93%), this was compared to 125 people out of 129 given placebo (97%).

According to these results, the difference that seems attributable to the giving of Vitamin E is a matter of about 4% (97% minus 93% = 4%).

Just round up or down to make it easy. Lets say, in this case, 5%.

So 5% of people in these trials seem to get some sort of improvement from Vitamin E – or put another way, 1 in 20, or put another way NNT = 20.
Vitamin E for neuroleptic-induced tardive dyskinesia

- FEEDBACK

Date and place of journal club

1. How many attended?

About

2. What was the background of the people attending? (please tick)

Health care professionals
Consumers
Policymakers
Undergraduate
Postgraduate
Others

3. Marks out of ten compared with usual journal club

(10 = much better, 5 = same, 0 = much worse)

Free text feedback

Thank you

This is one of 40 Cochrane Schizophrenia Group Guides for Journal Clubs

A full list is found on

http://szg.cochrane.org/journal-club